The nature of the metastatic disease, the short half-life of recombinant IL-2 and its preferential affinity for Tregs indicate that a high-dose bolus of intravenous IL-2 is needed, resulting in peripheral immune cell activation and systemic toxicity. The gene discussed is IL2; the disease is metastatic neoplasm.